

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	CRESO PHARMA LIMITED
ABN	89 609 406 911

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Adam Blumenthal
Date of last notice	9 June 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Anglo Australasia Holdings Pty Ltd <Anglo Australasia A/C> Atlantic Capital Holdings Pty <Atlantic Capital A/C> Both of the above entities are director-related entities.
Date of change	12 October 2020

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p>	<p><u>Direct:</u> Adam Blumenthal: 1 Fully Paid Ordinary Share</p> <p><u>Indirect:</u> Anglo Australasia Holdings Pty Ltd <Anglo Australasia A/C>: 6,250,000 Fully Paid Ordinary Shares</p> <p>Atlantic Capital Holdings Pty <Atlantic Capital A/C>: 1,958,387 Fully Paid Ordinary Shares 2,128,387 CPHOPT20 Options (\$0.35, 12 Feb 2023) 4,000,000 CPHOPT29 Options (\$0.25, 2 Jun 2023) 8,000,000 CPHOPT31 Options (\$0.20, 2 Jun 2023)</p>
<p>Class</p>	<p>Fully Paid Ordinary Shares</p>
<p>Number acquired</p>	<p>Anglo Australasia Holdings Pty Ltd <Anglo Australasia A/C>: 833,333 Fully Paid Ordinary Shares</p>
<p>Number disposed</p>	<p>Nil</p>
<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>\$0.06 per Share.</p>
<p>No. of securities held after change</p>	<p><u>Direct:</u> Adam Blumenthal: 1 Fully Paid Ordinary Share</p> <p><u>Indirect:</u> Anglo Australasia Holdings Pty Ltd <Anglo Australasia A/C>: 7,083,333 Fully Paid Ordinary Shares</p> <p>Atlantic Capital Holdings Pty <Atlantic Capital A/C>: 1,958,387 Fully Paid Ordinary Shares 2,128,387 CPHOPT20 Options (\$0.35, 12 Feb 2023) 4,000,000 CPHOPT29 Options (\$0.25, 2 Jun 2023) 8,000,000 CPHOPT31 Options (\$0.20, 2 Jun 2023)</p>

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>833,333 Shares issued on the same terms of the Placement completed by the Company on 3 June 2020, as approved by shareholders at the General Meeting held on 2 October 2020.</p> <p>Refer to the ASX announcement dated 1 June 2020 and the Appendix 3B "Proposed Issues of Securities" released on the same date, together with the Notice of Meeting lodged with the ASX on 27 August 2020.</p>
---	--

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

If prior written clearance was provided, on what date was this provided?	N/A
--	-----

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	CRESO PHARMA LIMITED
ABN	89 609 406 911

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Miri Halperin Wernli
Date of last notice	8 July 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Jorge Wernli <WHP Management Consulting AC> (spouse of Miri Halperin Wernli)
Date of change	12 October 2020
No. of securities held prior to change	Direct (Miri Halperin Wernli) 12,500,000 Fully Paid Ordinary Shares Indirect (Jorge Wernli <WHP Management Consulting AC>) 300,000 Fully Paid Ordinary Shares
Class	Fully Paid Ordinary Shares
Number acquired	833,333 Fully Paid Ordinary Shares
Number disposed	Nil.
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.06 per Share.

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

No. of securities held after change	Direct (Miri Halperin Wernli) 13,333,333 Fully Paid Ordinary Shares Indirect (Jorge Wernli <WHP Management Consulting AC>) 300,000 Fully Paid Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	833,333 Shares issued on the same terms of the Placement completed by the Company on 3 June 2020, as approved by shareholders at the General Meeting held on 2 October. Refer to the ASX announcement dated 1 June 2020 and the Appendix 3B "Proposed Issues of Securities" released on the same date, together with the Notice of Meeting lodged with the ASX on 27 August 2020.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.